Dr. Riemann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1945 Cei Drive
Cincinnati, OH 45242Phone+1 513-984-5133Fax+1 513-569-3941
Education & Training
- Cleveland Clinic FoundationResidency, Ophthalmology, 1995 - 1998
- York HospitalInternship, Transitional Year, 1994 - 1995
- University of Maryland School of MedicineClass of 1994
Certifications & Licensure
- KY State Medical License 1999 - 2026
- OH State Medical License 1995 - 2026
- PA State Medical License 1994 - 1995
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Treatment for Presumed Ocular Histoplasmosis Start of enrollment: 2013 Mar 01
Publications & Presentations
PubMed
- Postoperative Methotrexate to Reduce Reoperation Rate and Improve Vision in Patients With Complex Retinal Detachments, Advanced Diabetic Retinopathy, and Trauma.Lauren Gibson, Alyson Nguyen, Jared Ridgeway, Mariam Omar, Christopher Purvis
Journal of Vitreoretinal Diseases. 2025-03-18 - Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis s...Naveen R Ambati, Christopher D Riemann
American Journal of Ophthalmology Case Reports. 2024-12-01 - Pivotal Trial Toward Effectiveness of Self-administered OCT in Neovascular Age-related Macular Degeneration. Report 2-Artificial Intelligence Analytics.Eric W Schneider, Jeffrey S Heier, Nancy M Holekamp, Miguel A Busquets, Alan L Wagner
Ophthalmology Science. 2024-11-26
Press Mentions
- Ergonomics: Care for Yourself to Improve Patient CareAugust 31st, 2022
- Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care for DME PatientsJuly 26th, 2022
- Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.September 13th, 2021
- Join now to see all
Professional Memberships
- Fellow
External Links
- CEIhttp://www.cincinnatieye.com/doctors/christopher-d-riemann-m-d/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: